NDAORALCAPSULE
Approved
Oct 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOLECTIN DS is an oral nonsteroidal anti-inflammatory drug (NSAID) containing tolmetin sodium, approved in 1979 for the treatment of rheumatoid arthritis, osteoarthritis, and other inflammatory conditions. The drug works by inhibiting prostaglandin synthesis through COX enzyme inhibition, reducing inflammation and pain. It is formulated as a capsule for oral administration.
LOE Approaching
As a mature NSAID approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on managed decline and transition strategies rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TOLECTIN DS offers limited career advancement opportunities given the product's LOE-approaching status and zero linked job openings. Professionals on this brand are typically focused on portfolio transition, generic deflection, and managed decline rather than growth strategies.
Brand ManagerMarket Access Manager
Worked on TOLECTIN DS at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.